An *In silico* Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant

Abbas Ali Imani Fooladi 1; Hamideh Mahmoodzadeh Hosseini 1; Jafar Amani 1,*

1Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Jafar Amani, Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-2182482568, E-mail: jafar.amani@gmail.com

Received: September 29, 2014; Revised: November 16, 2014; Accepted: December 14, 2014

**Background:** Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.

**Objectives:** We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.

**Materials and Methods:** Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.

**Results:** Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

**Conclusions:** The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.

**Keywords:** ROR-1; Staphylococcus Enterotoxin B; Breast Neoplasms; Vaccines

1. Background

Breast cancer is one of the most common causes of death in women all around the world. It is estimated that more than 1.38 million new women suffered from breast cancer (1). Anti-estrogen therapy is the choice strategy for estrogen receptor positive breast cancer patients. However, a large number of breast cancers do not respond to this type of treatment because of lack of estrogen receptor. Furthermore, another group of breast cancer becomes insensitive to hormone therapy after first therapy and immediately promotes to grow (2). Although chemotherapy is an alternative strategy for treating insensitive and metastatic breast cancer, but many of the treated cancers often develop a recurrence. Therefore, innovating novel agents is an urgent requirement for attenuating the mortality rate (3). The receptor tyrosine kinase like orphan receptor 1 (ROR1) is a transmembrane protein and belongs to the receptor tyrosine kinase family (4). This protein has five domains, three extracellular including an immunoglobulin like motif, frizzled and Kringle domains, transmembrane part and an intracellular tyrosine kinase domain (5). Over expression of ROR1 is found in the embryonic stage (6) and several cancers including B-CLL (7), B-ALL (8), gastric carcinoma, non-small cell carcinoma cell lines (9) and breast cancer (10). Zhang et al. revealed the overexpression of ROR1 in the breast cancer related with lacked of HER2/neu and hormone receptors. Moreover, upregulation of ROR1 in primary breast cancer is associated with poor differentiation and shorter survival rate (10). There are limited or lack of ROR-1 in normal cells while over expression of this protein has been reported among human cancer cells, therefore ROR1 may be applied as a potent target for immunotherapy.

Staphylococcal enterotoxin B (SEB), a 28 KDa superantigen, is a powerful T cell activator. This protein binds to MHC class II on antigen presenting cells (APCs) and then forms complex with the variable region of β chain of T cell receptor. The binding site of SEB on the APCs has differed from that of specific antigens (11). SEB exerts a potent mitogenic effect on both CD4+ and CD8+, increasing cytokines including interferon-γ (INF-γ), interleukin 2 (IL-2), and tumor necrosis factor-α (TNF-α), finally promotes a powerful antitumor immunity (12).

One of the main goals of immunotherapy against tumor is to create a specific tumoral antigen response that participates to the tumor eradication. Designing the combined construct, enabling to activate both cellular
and humoral anti-tumor immunity is an effective therapeutic method which restricts or eradicates tumor progression. To date, it is possible to design a suitable combined construct, based on B cell and the T cell epitope map using bioinformatics methods.

2. Objectives

Here, we purposed to design the immunotherapeutic target constructed having two parts. The first one was extracellular domains of ROR1 as specific tumoral antigens for inducing B cell lymphocyte and second one is SEB, an adjuvant to create anti-tumoral response via T cell lymphocyte.

3. Materials and Methods

3.1. Protein Sequences and Designing the Construct

To obtain the protein sequences of ROR1 and SEB, the UniProtKB database was used. The accession number of SEB and ROR1 was P01552 and A2VCQ3, respectively. To make a fusion protein based on ROR1 and SEB having robust specific anti-tumoral activity, the extracellular part of ROR1 containing the frizzled domain and Ig-like C2 type domain was selected and joined to the complete sequence of SEB with GSGGSGGSGGSG as a hydrophobic amino acid linker. To survey the antigenicity of designed construct, the online database VaxiJen v2.6 was utilized.

3.2. The Physico-Chemical Characteristics

The physicochemical features, theoretical isolectric point (pI), molecular weight, total number of positive and negative residues, extinction coefficient, instability index, aliphatic index and grand average hydropathy of recombinant construct were analyzed by the Expasy ProtParam server (http://us.expasy.org/tools/protparam.html).

3.3. Prediction of Secondary Structure

To assess the secondary structure of ROR1-SEB fusion protein, the online database GOR IV (13) were performed. To confirm findings from Gor4, fusion proteins evaluated by PHDsec (https://www.predictprotein.org).

3.4. Prediction of 3D structure

The 3D model of the designed construct, was evaluated by the I-TASSER online server (14). To compute the Energy minimization and Ramachandran plot of the suggested 3D model, Swiss-PdbViewer and Procheck server (15) were executed.

3.5. Prediction of B-Cell and T-Cell Epitopes

To predict the linear and conformational B-cell epitopes, full-length primary sequences of designed fusion protein were computed using BCPreds (16) and web server CBTOPE (17), respectively. In addition, for prediction of discontinuous B-cell epitopes from three-dimensional protein structures, Discotope server was employed (18). Furthermore, to identify the antigenicity of selected BCPreds epitopes with the cutoff value of > 0.8, the VaxiJen (threshold = 0.4, ACC output) was used. On the other hand, BCPreds software was utilized for predicting continuous B cell epitopes based on different parameters including hydrophilicity, plasticity, exterior accessibility, antigenicity, flexibility, surface exposed, and polarity along full length designed construct. To survey MHC Class I and MHC Class II binding common epitopes, Propred (47 MHC Class I alleles) (19) and Propred (51 MHC Class II alleles) (20) servers was exerted, respectively. In accordance with two mentioned servers, the whole numbers of MHC allele interaction were estimated. The antigenicity value of predicted epitopes was analyzed by VaxiJen.

3.6. Prediction of Allergenic Regions

To recognize the possibility of existence of allergenic regions, AlgPred was used. The server predict allergens along the fusion protein sequence in accordance with similarity to known epitopes. Next the allergenicity was evaluated through SDAP database (21).

3.7. Prediction of Protein Solubility

To assess the protein solubility, the recombinant protein solubility prediction was exerted (22).

4. Results

4.1. Designing the Construct

The extracellular part of ROR1 was selected for designing the N-terminal of chimeric because of its accessibility to antigen presenting cells. This part has consisted of the frizzled domain, which involves in proliferation, cell polarity and cell developing, and Ig-like C2 type domain, which participates in cell-cell recognition and immune system stimulation. Full-length of SEB was conjugated with GSGGSGGSGGSGG as a hydrophobic amino acid linker. To survey the antigenicity of designed construct, the online database VaxiJen v2.6 was utilized.

Figure 1. Schematic representation of ROR1-SEB constructs containing two extracellular domains of ROR1 (Ig-like C2 type and Frizzled domain) and the whole sequence of SEB fusing together with a hydrophobic linker.
4.2. The Physico-Chemical Characteristics

Our construct has 517 amino acids consisting 65 negatively charged residues and 62 positively charged residues. Its molecular weight was 59,019.9 KDa. The value of pl was 6.42 that indicated the acidity feature of the designed construct. The extinction coefficient of ROR1-SEB was 58,065 M-1 cm-1 at 280 nm. The appraised half-life was > 10. In accordance with an instability index of ExPasy, ProtParam (< 40), ROR1-SEB was categorized as an unstable protein (instability index=41.90). The alphabetic index and Grand average of hydropathicity of ROR1-SEB was 70.48 and -0.527, respectively.

4.3. Prediction of Secondary Structure

Figure 2 illustrates the pattern of secondary structure of ROR1-SEB predicted by GOR IV. Based on our findings, the structural content of ROR1-SEB was composed of 18.64% alpha helix, 27.38% extended strands and 53.98% random coil. Full length of ROR1-SEB is made up of 33 random coils, 30 extended strands and 11 alpha helices. As summarized in Table 1, the secondary structure pattern of the chimeric protein is similar to the extracellular part of ROR1 and SEB.

4.4. Prediction of 3D Structure

As findings from I-TASSER server, five three-dimensional models were afforded for our designed protein fusing with GSGGSGGSGGSG as a linker. Figure 3 illustrates the best tertiary model predicted for describing protein, which has three separate parts and two domains. The confidence score, as a factor estimates the quality of suggested model was -2.22. What’s more, the expected TM- score and RMSD were 10.9 ± 4.6 Å and 0.53 ± 0.15, respectively. Additionally, we fused two proteins using (HDPVRVS) 2 as an alternative construct. I-TASSER results from predicting tertiary models for this alternative construct showed no appropriate structure therefore we exerted all our analysis only on the first construct. The Ramachandran plot assessment viewed that 80.2% (413 amino acids), 11.1% (57 amino acids) and 8.7% (45 amino acids) were situated in the favored region, allowed region and outlier region, respectively (Figure 4). The quality assessment of the Ramachandran plot revealed that more than 90% of residues located on acceptable (favored and allowed) regions. In accordance with Pdb Viewer analysis, the energy minimization amount was -9536.065 Kcal/mol that portended the plausible stability for our designed construct.

4.5. B-Cell Epitopes

Table 2 listed the epitopes predicted by BCpreds and AAPpreds within the full-length of designing protein. The appropriate epitopes were selected according to cutoff values of 0.8, 0.8 and 0.4 for BCpreds, AAPpreds and Vaxijen, respectively. Moreover, the conformational B cell epitopes were evaluated by two servers termed Discotope and CBTOPE and their data summarized in Tables 3 and 4, respectively. On the other hand, the predicted B cell epitopes were determined in accordance with different parameters including hydrophilicity, flexibility, accessibility, exposed surface, polarity and antigenic propensity with the respective thresholds of 1.9, 2.1, 2.4, 2.3, 1.8 and 1.9, respectively. As demonstrated in Table 5, although applied linker has been determined as a hydrophobe and flexible epitope, it showed no surface exposed epitope, having to interact with antibodies. Table 6 summarizes the predicted epitopes, which can simultaneously interact with B cell, MHC class I and class II with the highest number.

4.6. Allergenicity Property

Based on outcome from AlgPred and SDAP database, our construct viewed no allergenic sites along its sequence. Furthermore, it had no great similarity to the allergen listed in SDAP library.

4.7. Protein Solubility Prediction

According to outputs from recombinant protein solubility prediction, our designed construct possesses 36.6% a solubility chance after overexpressin in E.coli.

---

Table 1. Pattern of Secondary Structure of Origin and Chimeric Proteins

| Protein                  | Extended Strand | Alpha Helix | Random Coil |
|-------------------------|-----------------|-------------|-------------|
| ROR1 (extracellular part)| 26.78           | 9.62        | 63.60       |
| SEB                     | 28.95           | 25.19       | 45.86       |
| ROR1-SEB                | 27.38           | 18.64       | 53.98       |

a Data are presented as %.
Figure 3. A Probabilistic Structural Model for Chimeric Protein Using I-TASSER Software

As illustrate in figure two domains of Ror1 (in the left site) separate with the linker from SEB fragment (in the right site).

Figure 4. A Feature of Ramchandran Plot for the ROR1-SEB Chimeric Protein

Table 2. B-Cell Epitopes Mapping by BCpred Results (BCPred + AAP)

| Position | BCpred Epitope               | Score | Vaxijen | Position | AAPpred Epitope               | Score | Vaxijen |
|----------|----------------------------|-------|---------|----------|----------------------------|-------|---------|
| 89       | KFGPPPTASPQYDSEYEEDG       | 1     | 0.1212  | 279      | ESQPDPKPKDELHKSSKFTGL      | 1     | 0.9262  |
| 240      | GSGGGSGSGGGSMYKRLFIS       | 1     | 0.8888  | 34       | NDAPVQEPRLSFRSTIYG        | 1     | 1.0983  |
| 498      | NKMVDSDKVDKIEVYLTKKK       | 1     | 0.7183  | 494      | MYNDNKMVDSKVDKIEVYLT      | 1     | 0.3562  |
| 23       | GNPPPTIRWFKNAPVQEP         | 0.999 | 0.8779  | 88       | VKGPPTASPQYDSEYEEDG       | 1     | 0.0531  |
| 278      | AESQPDPKPKDELHKSSKFTG      | 0.968 | 0.7827  | 468      | IENENSFWYMMPAPGDKFQ       | 1     | 0.6351  |
| 216      | RLKLPNCDLPQPESEAN          | 0.915 | 0.7060  | 226      | PQPESPEANAIRSGGGSG         | 1     | 1.1506  |
| 1        | DEPMNNITSLGQTAELHCK        | 0.881 | 0.8571  | 12       | GQTAELHCKVS Fields        | 1     | 1.0859  |
| 470      | NENSFYDMMPAPGDKFQ          | 0.868 | 0.5261  | 392      | MYGTVETGNQLDKYRSIT        | 1     | 1.4149  |
| 167      | LCHAFPYCDETSSVPKPRD        | 0.867 | 0.6159  | 351      | LADYKDKYDVFGANYYYQ         | 0.869 | 0.3303  |
| 353      | DKKYKDYDVFVAGANYYYQC       | 0.805 | 0.3624  | 62       | DTDTGYFQCVATNGKEVS         | 0.092 | 0.6347  |
| 374      | SKKTNDINSHQDKRKTCKMY       | 0.788 | 0.2889  |          |                             |       |         |
| 63       | TTDTGYYFQCVATNGKEVS        | 0.779 | 0.6283  |          |                             |       |         |
| 331      | IKDALTGNYDNVRVEFKNDK       | 0.74  | 1.0925  |          |                             |       |         |
| Amino Acid | Position | Contact Number | Discotope Score |
|------------|----------|----------------|----------------|
| DEPMNN     | 1-6      | 1,16, 7, 19, 14, 6 | 0.515, -0.842, 0.634, -1.893, -1.431, -1.81 |
| TTSLGQT    | 8-14     | 9,15, 4, 0, 2, 8, 3 | -2.375, -3.332, -4.213, -0.741, 0.858, -2.744, -2.486 |
| ELHCKVSNPPPTIRW | 16-31 | 12,22,14, 21, 6, 20, 2, 14, 2, 4, 0, 8,10, 16, 16, 15 | -3.248, -3.584, -2.197, -2.664, 0.005, -1.425, 1.683, 1.138, 2.601, 2.668, 0.036, 2.322, 1.075, -0.466, -1.82, -3.433 |
| EPRLIS     | 41-46    | 3, 0, 2, 9, 16, 2 | -3.138, -1.218, -0.279, -0.751, -2.35, -0.849 |
| RST       | 48-50    | 2, 15, 1 | -3.321, -3.416, -2.109 |
| GS        | 53-54    | 5, 2 | -2.35, -3.299 |
| DT        | 65-66    | 0, 3 | -2.461, -2.745 |
| GSP       | 91-92    | 5, 2 | -2.365, -3.229 |
| GP        | 94-95    | 12, 3 | -2.906, -2.069 |
| PT        | 97-98    | 0, 3 | -0.66, -2.636 |
| QPESP     | 227-231  | 3, 10, 3, 7, 1 | -2.599, -2.678, -2.72, -1.993, -2.921 |
| GS2GS2G33GSM | 240-252 | 7, 13, 8, 11, 3, 9, 10, 4, 3, 5, 6, 8, 12 | -0.897, -1.514, 0.086, 1.325, 3.212, 1.298, 0.689, 1.171, 0.916, -0.147, -1.799, -3.045, -3.294 |
| QPDPRPDELH KSSKFGILME N | 281-301 | 18, 12, 9, 5, 8, 20, 7, 26, 26, 9, 28, 8, 12, 31, 2, 15, 7, 23, 4, 23 | -3.327, -2.155, -1.736, 0.317, 4.474, 3.591, 3.562, 5.622, 1.649, 2.357, 5.92, 2.29, 5.097, 4.013, 1.748, 4.057, 2.026, 2.515, 0.336, 1.913, -1.357 |
| KV       | 303-304  | 20, 13 | -3.060, -2.894 |
| DD       | 307-308  | 13, 6 | -3.677, -3.135 |
| INVKSIDQF | 304-322  | 5, 6, 24, 6, 34, 25, 21, 16, 21 | 0.162, 0.84, -2.321, 1.272, -2.386, -2.222, -1.957, -1.63, -3.409 |
| Y        | 324      | 5 | -2.481 |
| N        | 328      | 18 | -2.524 |
| S        | 330      | 13 | -0.9 |
| KDTKLNODYN | 332-341 | 4, 24, 3, 7, 14, 2, 24, 10, 24 | -0.679, -3.185, -0.989, -1.087, -1.69, 0.423, -1.37, 2.883, -1.848, -2.874 |
| NKD      | 348-350  | 6, 1, 3 | -2.495, -4.55, 0.181 |
| ADK      | 352-354  | 20, 3, 17 | -3.396, -0.961, -4.437 |
| KDYV Y D | 356-361  | 15, 2, 21, 7, 3, 18 | -1.009, 2.356, 0.582, 0.301, -3.061, -2.35 |
| YQ       | 369-370  | 14, 13 | -2.388, -2.661 |
| Y        | 372      | 1 | -1.614 |
| SKKNDNHSQT KDKRK | 374-389 | 5, 23, 14, 17, 4, 0, 11, 2, 0, 2, 14, 2, 3, 27, 13, 24 | -0.966, -2.474, 0.302, 0.523, 0.492, 2.571, 5.378, 5.726, 5.674, 1.902, 3.401, 3.032, -1.421, -1.065, -3.076 |
| TEHNGNOJDV K YRS | 397-409 | 30, 10, 18, 6, 4, 25, 10, 16, 0, 5, 10, 23, 7 | -3.34, 0.052, 0.2, 2.671, 2.901, -0.58, 1.283, 0.41, 2.285, 0.737, -0.385, -2.808, -2.969 |
| EDK      | 416-419  | 15, 7, 1, 4 | -2.338, 1.239, -0.095, -3.019 |
| Q        | 427      | 8 | -3.343 |
| NKKK     | 429-432  | 14, 26, 9, 16 | 0.718, -1.554, 1.49, 1.2 |
| N        | 449      | 20 | -3.366 |
| K        | 451      | 13 | -1.034 |
| YEKNNSPY ETGY | 453-464 | 27, 13, 0, 2, 9, 38, 10, 29, 12, 16, 31, 23 | -1.439, 0.886, 4.002, 4.59, 2.755, -0.519, 2.565, -0.529, 3.315, 1.136, -1.455, -4.643 |
| YD       | 476-477  | 28, 21 | -3.446, -1.018 |
| MPAPGDKFD | 479-487  | 30, 30, 10, 11, 5, 0, 6, 29, 10 | 0.017, 1.22, 4.186, 4.109, 1.864, 4.093, 2.213, -0.442, 0.496 |
| K        | 490      | 9 | -2.104 |
| ND       | 496-497  | 17, 9 | -3.3, -2.01 |
| K        | 499      | 18 | -2.508 |
| D        | 502      | 9 | -2.631 |
| K        | 504      | 8 | -3.009 |
| YLTTKKK  | 518-517  | 17, 27, 16, 8, 12, 8, 8 | -3.5, -3.402, 0.009, 1.758, 3.135, 3.925, 2.506 |
### Table 4. Conformational B-Cell Epitopes Predicting by CBTOPE Server

| Amino acid | Position | Probability Scale | Amino Acid | Position | Probability Scale | Amino Acid | Position | Probability Scale |
|------------|----------|-------------------|------------|----------|-------------------|------------|----------|-------------------|
| DEPM       | 1-4      | 4                 | M          | 129      | 5                 | VFGAN      | 362-366 | 4                |
| HC         | 18-19    | 4                 | ESLH       | 130-133  | 4                 | YYQCYFSKTNDI | 368-380 | 4                |
| V          | 21       | 4                 | M          | 134      | 5                 | S          | 382      | 4                |
| S          | 22       | 6                 | QG         | 135-136  | 4                 | QT         | 384-385 | 4                |
| GN         | 23-24    | 5                 | NQITAA     | 140-145  | 4                 | D          | 386      | 5                |
| P          | 25       | 4                 | M          | 148      | 4                 | K          | 387      | 7                |
| P          | 26       | 5                 | T          | 151      | 4                 | R          | 388      | 5                |
| P          | 27       | 4                 | S          | 152      | 5                 | K          | 389      | 6                |
| T          | 28       | 5                 | SH         | 153-154  | 4                 | TC         | 390-391 | 5                |
| IRWFKN     | 29-34    | 4                 | C          | 159      | 4                 | M          | 392      | 4                |
| PTVQEPRLS  | 37-46    | 4                 | PSLCHYAPYC | 165-175  | 4                 | YGGVTEH    | 393-398 | 5                |
| I          | 51       | 4                 | DETS       | 176-179  | 5                 | NGNQLDKY   | 400-407 | 6                |
| RLRRI      | 55-58    | 4                 | SVPKPRDLCRDE | 180-191 | 4                 | R          | 408      | 7                |
| NLDT       | 60-63    | 4                 | C          | 192      | 5                 | S          | 409      | 6                |
| T          | 66       | 4                 | EILENVLCQTEYH | 193-205 | 5                 | IT         | 410-411 | 5                |
| G          | 67       | 5                 | PESPEANCI  | 228-237  | 4                 | V          | 412      | 4                |
| YF         | 68-69    | 4                 | V          | 276      | 4                 | G          | 418      | 4                |
| VAT        | 72-74    | 4                 | AESQDPKPKDEL | 278-289 | 4                 | SFDV       | 423-426 | 4                |
| GK         | 76-77    | 4                 | H          | 290      | 5                 | LV         | 446-447 | 4                |
| SST        | 81-83    | 4                 | KSS        | 291-293  | 4                 | K          | 448      | 5                |
| PIA        | 94-96    | 4                 | MENMK      | 299-303  | 4                 | NKKLYEFN   | 449-456 | 4                |
| SDEYEEDGF  | 101-109  | 4                 | LY         | 305-306  | 4                 | DQSKYLMYY  | 487-495 | 4                |
| C          | 110      | 5                 | D          | 308      | 4                 | D          | 497      | 4                |
| QP         | 111-112  | 4                 | H          | 310      | 4                 | KMVDSKD    | 499-505 | 4                |
| ARFI       | 119-122  | 4                 | TKLGNY     | 334-339  | 4                 | KI         | 507-508 | 4                |
| RT         | 125-126  | 4                 | NV         | 341-342  | 4                 | Y          | 511      | 4                |
| V          | 127      | 5                 | VEFKN      | 344-348  | 4                 |            |          |                  |
| Y          | 128      | 4                 | DL         | 350-351  | 4                 |            |          |                  |

### Table 5. Findings From Bcepred Software for B-Cell Epitope Based on Discrepant Parameters

| Prediction Parameters | Epitope Position |
|-----------------------|------------------|
| Hydrophilicity        | 59 - 68, 97 - 108, 135 - 141, 174 - 182, 226 - 235, 240 - 252, 278 - 288, 307 - 313, 347 - 359, 374 - 391, 397 - 406, 425 - 423, 456 - 463, 483 - 490, 496 - 503 |
| Flexibility           | 153 - 159, 172 - 181, 237 - 250, 277 - 283, 287 - 295, 362 - 370, 372 - 388, 423 - 431, 481 - 487, 499 - 505, 510 - 517 |
| Accessibility         | 1 - 7, 22 - 49, 54 - 68, 89 - 109, 124 - 130, 135 - 141, 177 - 190, 217 - 235, 278 - 297, 303 - 312, 329 - 361, 363 - 392, 396 - 410, 412 - 418, 423 - 494, 500 - 517 |
| Exposed surface       | 40 - 46, 101 - 107, 179 - 185, 279 - 294, 329 - 335, 342 - 361, 372 - 391, 401 - 409, 425 - 437, 445 - 456, 484 - 491, 499 - 505, 511 - 517 |
| Polarity              | 14 - 22, 38 - 49, 53 - 61, 100 - 109, 133 - 139, 182 - 196, 254 - 266, 282 - 296, 340 - 361, 382 - 393, 413 - 419, 426 - 437, 442 - 456, 465 - 472, 484 - 490, 499 - 517 |
| Antigenic propensity  | 16 - 23, 37 - 43, 66 - 72, 74 - 92, 164 - 170, 191 - 204, 255 - 265, 276 - 278, 319 - 331, 357 - 364, 366 - 375, 409 - 416, 427 - 430, 440 - 448, 505 - 514 |
Development of efficacious therapeutic strategy for some of the resistant malignancies is the main emergency of health organization all around the world. Nowadays, design of appropriate and safe vaccines which stimulate the immune response actively or passively, are the hot topic in the field of reverse vaccinology. This area is closely related to computational vaccinology that recruits discrepant informatics tools to predict efficient T- and B-cell functional epitopes to improve the properties of an antigen based vaccine (24, 25).

The principal purpose of the current study was to design a unique construct, including two antigenic parts, which adjoined together through hydrophobic linker (26, 27). Theoretically, our structural model could augment immunogenicity of ROR-1 protein and owing to the presence of staphylococcal enterotoxin B as a potent superantigen; its probability evokes a wide cellular or humoral anti-tumor immune response. As respects to the momentous role of linker in representing the pattern of various epitopes throughout the chimeric protein besides maintenance of its functional properties, the linker selection is a key point in designing of the fusion protein (26). In this study a flexible linker, GSGGSGGSGGSG With 12aa, was used to separate domains of two proteins. Aria et al. repotted the multimerizing property of short helical linker compared with longer ones. Furthermore, a flexible linker based on shorter conformation plays an efficient role in comparison to those with the helical linker (26). To predict the secondary structure of a chimeric protein, the GOR method was applied. This software allows estimating the possible secondary structure of each amino acid together with its impact on the condition and structure of adjacent amino acids. The most abundant structure within our fusion protein was a random coil that could be due to the presence of a high amount of hydrophobic amino acids such as glyc. In accordance with finding from the physico-chemical parameter analysis, our fusion protein had an acidic nature with the high extinction coefficient at 280 nm, which is owing to high content of Cys, Trp and Tyr. In contrast to partial instability of our fusion protein, its estimated high alphabetic index infers to protein stability in a broad range of temperature.

5. Discussion

One of the most important problems in the designing of recombinant protein is the biologic functional characteristics. Although prediction of secondary structure by ab-initio methods or folding recognition is able to detect some of the limitations (28), prediction of three-dimensional structure through comparative and ab-initio methods attenuates several errors (29, 30). The three-dimensional model of the fusion protein ROR-1-SEB protein was accounted using the I-TASSER server (14) according to their confidence score (C-score), Z-score, RMSD and TM-score. This server suggests five models for our chimeric sequence that model 2 had more c-score between them, therefore it selected for further evaluation. Expected TM-score obtained 0.53 ± 0.15, which accredited the validity of the model. A TM-score more than 0.5 portend accuracy of topology. Data from Pro-check Ramachandran plot demonstrated the stability of the fusion protein. Thereabout, 8.7% of the residues located in outline region, which, could presumably be owing to fusion. Since the purpose of designing a vaccine is the generation and selection of a candidate with the potential stimulation of strong responses (31), we analyzed the epitope maps for B cell and T cells. At first, we predicted linear B-cell epitope overall the chimeric sequence using BCpreds. Moreover, for recognizing the epitopes involved in antibody-antigen interaction, the estimation of conformational epitopes is an essential in the computational vaccine design which executed using both structure and sequence information based method, including DiscoTope and CBTOPE, respectively. Our result showed the copious b-cell epitopes, though some of the solely predicted by one method. In order to predict the map of T-cell epitope and binding affinity to both classes of MHC molecules, Propred and Propred-1 were applied. Numerous T-cell epitope with a high antigenicity score were suggested by two methods, but we only selected those epitope that is simultaneously proposing as B-cell and T-cell epitope (Table 6). Our result suggested that our structural model represented the epitope that are capable to be a stimulant for both T-cell and B-cell mediated immune responses. At last, this structure showed no significant resemblance with the allergen in the SDAP library.

Table 6. The List of Epitopes Having Both the B- and T-Cell Immune Responses Throughout the Length of the ROR1-SEB Chimeric Protein

| Sequence      | Number of Mhc Class I Binding Alleles | Number of MHC Class II Binding Alleles | Vaxijen Scores | Total Number of MHC Binding Alleles |
|---------------|--------------------------------------|---------------------------------------|----------------|------------------------------------|
| PMNNITITSL    | 3                                    | 30                                    | 0.5520         | 33                                 |
| VEFKNKND      | 14                                   | 26                                    | -0.2150        | 40                                 |
| ATNGKEVV      | 4                                     | 5                                     | 0.6692         | 9                                  |
| ESPEAANCI     | 14                                   | 0                                     | 0.6486         | 14                                 |
| NGKEVVss      | 5                                     | 6                                     | -0.2295        | 11                                 |
Acknowledgements
This work was supported by Baqiyatallah University of Medical Sciences, Applied Microbiology research Center.

Financial Disclosure
The authors declare that they have no competing interest.

Conflict of Interest
The authors made no disclosures.

References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogesterins in breast cancer treatment: are we ready? Endocr Relat Cancer. 2012;19(7):R35-50.
3. Soto-Cerrato V, Ilagostera E, Montaner B, Scheffer GL, Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the antitumor agent prodigiosin. Biochem Pharmacol. 2004;68(7):1345-52.
4. Forrester WC, Dell M, Perens E, Garriga G. A. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division. Nature. 1999;400(6747):283-5.
5. Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy. Front Oncol. 2012;2:34.
6. Al-Shawi R, Ashton SV, Underwood C, Simons JP. Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol. 2001;211(4):161-71.
7. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase RORi in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14(2):396-404.
8. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Farahmoush M, Ghraogholou S, et al. Expression profile of orphan receptor tyrosine kinase (RORi) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49(7):1360-7.
9. Gentile A, Lazzari I, Benvenuti S, Trusolino I, Comoglio PM. Rort is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 2011;71(8):3132-41.
10. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012;7(3):e31127.
11. Fooladi AA, Sattari M, Hassan ZM, Mahdavi M, Azizi T, Horii A. In vivo induction of necrosis in mice fibrosarcoma via intravenous injection of type B staphylococcal enterotoxin. Biotechnol Lett. 2008;30(12):2053-9.
12. Perabo FG, Willert PL, Wirger A, Schmidt DH, Wardelmann E, Sitzia M, et al. Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. Int J Cancer. 2005;115(4):591-8.
13. Sen TZ, Jernigan RL, Garnier J, Kloczkowski A. GOR V server for protein secondary structure prediction. Bioinformatics. 2005;21(1):278-78.
14. Zhang Y, TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9:40.
15. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(3):283-90.
16. El-Manzalawy Y, Dobbs D, Honavar V. Predicting linear B-cell epitopes using string kermels. J Mol Recognit. 2008;21(4):243-55.
17. Ansari HR, Raghava GP. Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res. 2010;6:6.
18. Haste Andersen P, Nielsen M, Lund O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci. 2006;15(1):258-67.
19. Singh H, Raghava GP. ProPred: prediction of promiscuous MHC Class-I binding sites. Bioinformatics. 2003;19(8):1009-14.
20. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17(2):323-7.
21. Ivanciuc O, Schein CH, Braun W. SDAP: database and computational tools for allergenic proteins. Nucleic Acids Res. 2003;31(1):159-62.
22. Davis GD, Elisee C, Newham DM, Harrison RG. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol Bioeng. 1999;65(4):382-8.
23. Ren J, Wen L, Gao X, Jin C, Xue Y, Yao X. DOG 1.0: illustrator of protein domain structures. Cell Res. 2009;19(2):273-1.
24. De Groot AS, Bhai H, Aubin CS, McMurry J, Martin W. Immuno-informatics: Mining genomes for vaccine components. Immunol Cell Biol. 2002;80(3):255-69.
25. Ho Y, Cao Z, De Groot AS, Brusic V, Schonbach C, Petrovsky N. Computational vaccination and the ICoVax 2012 workshop. BMC Bioinformatics. 2013;14 Suppl 4:e17.
26. Ari R, Wriggers W, Nishikawa Y, Nagamune T, Fujisawa T. Conformations of variably linked chimeric proteins evaluated by synchrotron X-ray small-angle scattering. Proteins. 2004;57(4):329-38.
27. Ari R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Fusion Eng. 2001;14(8):539-32.
28. Soria-Guerra RE, Moreno-Fierros I, Rosales-Mendoza S. Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches. Plant Cell Rep. 2011;30(4):3167-82.
29. Webb B, Sali A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinformatics. 2014;47S:6-1-5 6 32.
30. Petsko GA. An introduction to modeling structure from sequence. Curr Protocols Bioinform. 2006;6:1.1-3.
31. Negi SS, Braun W. Automated detection of conformational epitopes using phage display Peptide sequences. Bioinform Biol Insights. 2009;3:71-81.